VOL. XCIV, NO. 247

* WIDE MOAT STOCKS COMPARISON *

NO ADVICE

Monday, December 29, 2025

Stock Comparison

Agilent Technologies, Inc. vs Sartorius Stedim Biotech S.A.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

Agilent Technologies, Inc.

A · New York Stock Exchange

Market cap (USD)$38.9B
SectorHealthcare
CountryUS
Data as of2025-12-22
Moat score
65/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Agilent Technologies, Inc.'s moat claims, evidence, and risks.

View A analysis

Sartorius Stedim Biotech S.A.

DIM · Euronext Paris

Market cap (USD)$23.6B
SectorHealthcare
CountryFR
Data as of2025-12-28
Moat score
80/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Sartorius Stedim Biotech S.A.'s moat claims, evidence, and risks.

View DIM analysis

Comparison highlights

  • Moat score gap: Sartorius Stedim Biotech S.A. leads (80 / 100 vs 65 / 100 for Agilent Technologies, Inc.).
  • Segment focus: Agilent Technologies, Inc. has 3 segments (41.9% in Agilent CrossLab); Sartorius Stedim Biotech S.A. has 2 segments (75% in Sterile single-use bioprocessing consumables).
  • Primary market structure: Competitive vs Oligopoly. Pricing power: Strong vs Strong.
  • Moat breadth: Agilent Technologies, Inc. has 5 moat types across 2 domains; Sartorius Stedim Biotech S.A. has 6 across 3.

Primary market context

Agilent Technologies, Inc.

Agilent CrossLab

Market

Laboratory services, compliance/maintenance, consumables and lab informatics across the lab workflow

Geography

Global

Customer

B2B (installed base labs across pharma, diagnostics, academia and applied markets)

Role

Aftermarket services + consumables + informatics

Revenue share

41.9%

Sartorius Stedim Biotech S.A.

Sterile single-use bioprocessing consumables

Market

Sterile single-use bioprocessing consumables (bags, filters, fluid management components)

Geography

Global

Customer

Biopharmaceutical manufacturers and CDMOs

Role

Consumables supplier (single-use)

Revenue share

75%

Side-by-side metrics

Agilent Technologies, Inc.
Sartorius Stedim Biotech S.A.
Ticker / Exchange
A - New York Stock Exchange
DIM - Euronext Paris
Market cap (USD)
$38.9B
$23.6B
Sector
Healthcare
Healthcare
HQ country
US
FR
Primary segment
Agilent CrossLab
Sterile single-use bioprocessing consumables
Market structure
Competitive
Oligopoly
Market share
n/a
10%-25% (implied)
HHI estimate
n/a
n/a
Pricing power
Strong
Strong
Moat score
65 / 100
80 / 100
Moat domains
Demand, Supply
Demand, Supply, Legal
Last update
2025-12-22
2025-12-28

Moat coverage

Shared moat types

Design In QualificationInstalled Base Consumables

Agilent Technologies, Inc. strengths

Brand TrustService Field NetworkData Workflow Lockin

Sartorius Stedim Biotech S.A. strengths

Learning Curve YieldCompliance AdvantageSuite BundlingCapex Knowhow Scale

Segment mix

Agilent Technologies, Inc. segments

Full profile >

Life Sciences and Diagnostics Markets

Oligopoly

39.2%

Agilent CrossLab

Competitive

41.9%

Applied Markets

Oligopoly

18.9%

Sartorius Stedim Biotech S.A. segments

Full profile >

Sterile single-use bioprocessing consumables

Oligopoly

75%

Bioprocessing equipment, systems, and software/services

Oligopoly

25%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.